Axelson, Michael <br/><br/>
U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  May 2013 
 - 2289-93 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-12-1956  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Anilides--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Basal Cell--drug therapy<br/>Drug Approval<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multicenter Studies as Topic<br/>Neoplasm Recurrence, Local--drug therapy<br/>Pyridines--adverse effects<br/>Skin Neoplasms--drug therapy<br/>United States<br/>United States Food and Drug Administration<br/>Young Adult